Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC71H119N17O31 |
InChIKeyNOGWFLAKIOHPHB-ZRWVUPPZSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 1 | China | 25 Jun 2024 |
Not Applicable | HER2-positive | - | yojilzuuif(dzrpnyiwiz) = dzassviera qorlhgoipn (ljtzsxqeby ) | - | 07 Dec 2024 | ||
yojilzuuif(dzrpnyiwiz) = gergzkljiw qorlhgoipn (ljtzsxqeby ) |